GRB2
GRB2 (Growth factor receptor-bound protein 2) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms and Chronic myeloid leukaemia.
Overview
Non-enzymatic adapter protein that plays a pivotal role in precisely regulated signalling cascades from cell surface receptors to cellular responses, including signalling transduction and gene expression. Thus, participates in many biological processes including regulation of innate and adaptive immunity, autophagy, DNA repair or necroptosis. Controls signalling complexes at the T-cell antigen receptor to facilitate the activation, differentiation, and function of T-cells.
Open Targets scores its association with cancer at 0.69 (direct and indirect evidence; datatypes literature 0.97, affected pathway 0.88, genetic association 0.00, clinical 0.18).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · GRB2 (Growth factor receptor-bound protein 2) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms and Chronic myeloid leukaemia.
- 1 · What it is
GRB2 (Growth factor receptor-bound protein 2) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms and Chronic myeloid leukaemia.
- 2 · What goes wrong in cancer
Non-enzymatic adapter protein that plays a pivotal role in precisely regulated signalling cascades from cell surface receptors to cellular responses, including signalling transduction and gene expression.
- 3 · How drugs use it
No product in this corpus aims at GRB2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:4566 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P62993 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000177885 (association with cancer (MONDO_0004992) 0.69; per-cancer scores at or above 0.5: chronic myelogenous leukaemia, BCR-ABL1 positive 0.55, myeloproliferative neoplasm 0.59, leukaemia 0.59 (GraphQL API, CC0))
Biology
Non-enzymatic adapter protein that plays a pivotal role in precisely regulated signalling cascades from cell surface receptors to cellular responses, including signalling transduction and gene expression. Thus, participates in many biological processes including regulation of innate and adaptive immunity, autophagy, DNA repair or necroptosis. Controls signalling complexes at the T-cell antigen receptor to facilitate the activation, differentiation, and function of T-cells. Mechanistically, engagement of the TCR leads to phosphorylation of the adapter protein LAT, which serves as docking site for GRB2. In turn, GRB2 establishes a a connection with SOS1 that acts as a guanine nucleotide exchange factor and serves as a critical regulator of KRAS/RAF1 leading to MAPKs translocation to the nucleus and activation. Functions also a role in B-cell activation by amplifying Ca(2+) mobilisation and activation of the ERK MAP kinase pathway upon recruitment to the phosphorylated B-cell antigen receptor (BCR). Location: Nucleus; Cytoplasm; Endosome; Golgi apparatus (UniProt). Locus 17q25.1 (HGNC).
- Leukaemia: Open Targets association 0.59 with leukaemia (MONDO_0005059)
- Myeloproliferative neoplasms: Open Targets association 0.59 with myeloproliferative neoplasm (MONDO_0020076)
- Chronic myeloid leukaemia: Open Targets association 0.55 with chronic myelogenous leukaemia, BCR-ABL1 positive (MONDO_0011996)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.18. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"GRB2" OR ABSTRACT:"GRB2" OR TITLE:"growth factor receptor bound protein 2" OR ABSTRACT:"growth factor receptor bound protein 2" OR TITLE:"Growth factor receptor-bound protein 2" OR ABSTRACT:"Growth factor receptor-bound protein 2" OR TITLE:"NCKAP2" OR ABSTRACT:"NCKAP2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GRB2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetGAB2
Shares BCR::ABL1 (Philadelphia chromosome), Chronic myeloid leukaemia (KEGG map), Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TargetFGR
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Open Targets Platform.
- TargetFYN
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Open Targets Platform.
- TargetSRMS
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Open Targets Platform.
- TargetBLK
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Open Targets Platform.
- TargetRPS29
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Open Targets Platform.
- TargetIFNAR2
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Open Targets Platform.
- TargetYES1
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Open Targets Platform.